Management Team

Our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to finance and investment banking. This combination of skill sets enables the team to effectively execute our business plan.

Annalisa-Jenkins.png

Dr. Annalisa Jenkins, MBBS, FRCP

Executive Chair

DavidEllam_160sq_circle.png

David Ellam

Chief Financial Officer

Dr. Annalisa Jenkins, MBBS, FRCP

Executive Chair

Dr. Jenkins is a biopharma thought leader with 25 years of industry experience. Until November 2017, she was President and Chief Executive Officer at leading gene therapy company, Dimension Therapeutics. Prior to joining Dimension in September 2014, Annalisa served as head of global research and development at Merck Serono Pharmaceuticals from 2013 to 2014, where she also served as executive vice president global development and medical from 2011 to 2013. Prior to this, Dr. Jenkins held several leadership roles at Bristol Myers-Squibb from 1997 to 2011, most recently serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander.

Annalisa-Jenkins.png

Appointed

October 2017

Areas of expertise

Drug development, R&D, regulatory approval and commercialisation

Current external roles

President and Chief Executive Officer of PlaqueTec Limited. Non-Executive Director of Ardelyx Inc, Iox Therapeutics Limited, Oncimmune Holdings plc, Thrombolytic Science International, PhESi LLC and AVROBIO Inc. Chair of Vium Inc, Cocoon Biotech Inc and Cell Medica Limited. Committee member of the U.S. Food & Drug Administration Science Board.

David Ellam

Chief Financial Officer

David was appointed Chief Financial Officer and Company Secretary of Silence in July 2016. David holds a B.A. in English & Philosophy from Birmingham University, and is a qualified chartered accountant.

Prior to joining Silence, David’s relevant Biotech experience includes several senior finance roles within both UK and US publicly owned life science companies, most recently as Senior EUMEA Finance Director for BioMarin Pharmaceuticals Inc. from 2010 to 2016. Prior to that he was CFO at Plethora Solutions plc (2008-2009), and Group Financial Controller at Ark Therapeutics from 2001 to 2008, during which time Ark undertook an IPO on the London Stock Exchange.

DavidEllam_160sq_circle.png

Appointed

July 2016

Areas of expertise

Finance, applied to the biotechnology industry.

Current external roles

None